NEPHRIX Biosolutions, the renal preclinical CRO that de-risks clinical studies

10% of the population is affected by CKD (Chronic Kidney Disease), which is a leading cause of mortality and morbidity around the world. Patients with renal diseases often face delayed diagnosis and a scarcity of medications addressing the underlying causes of the condition, with current treatments primarily addressing symptoms alone. Despite substantial investments and efforts in developing new therapies, pharmaceutical companies encounter a significant rate of failures in clinical trials, largely attributed to ineffective preclinical evaluations.
To address this gap, NEPHRIX Biosolutions offers preclinical CRO services dedicated to renal disease research, combining physiologically relevant in vitro assays with in vivo kidney models to help drug developers make better decisions, earlier.

Kidney models and assays mapped to the disease course

NEPHRIX Biosolutions combines disease-relevant in vitro systems with in vivo models tuned to Chronic Kidney Disease (CKD), Acute Kidney Injury (AKI) & Diabetic Kidney Disease (DKD) preclinical research.

DuoXProx

Our proprietary co-culture system, applied across models to keep readouts - KIM-1, NGAL, GFR and beyond - comparable from one disease stage to the next.

Fibrosis assay

In vitro assays using human primary fibroblasts from different origins (renal, lung, cardiac or skin).

Cisplatin Model

Chemically induced AKI model used to evaluate nephrotoxic potential and protective compounds against tubular injury.

UUO Model

Unilateral ureteral obstruction, the reference model for renal fibrosis progression, used to assess anti-fibrotic candidates on a predictable, accelerated timeline.

FibrosisCollagen deposition

IRI Model

Surgically induced AKI model reproducing the ischemic insult and reperfusion phase seen in clinical acute kidney injury.

Our models

Our mission is to bring our technical and scientifiic expertise for the success of your project

Discover our solutions